Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight ...

OTR Therapeutics may still be keeping its own pipeline under wraps, but Zealand Pharma has seen enough promise in the Chinese ...

The FDA’s oversight of medical device recalls continues to be plagued by staffing challenges—forcing some activities to be ...

Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned ...

Existing IPF treatments, including Boehringer’s recently approved Jascayd, slow disease progress rather than halt or reverse ...

After securing Medicare reimbursement for its pacemaker-like heart failure (HF) implant, Impulse Dynamics has raised more ...

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...

After receiving word late last month that the FDA would not be issuing a 510(k) clearance to its cable-free electrocardiogram ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain ...

Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...

Rival European pharma giants Sanofi and GSK have both forged new partnerships to bolster their preclinical research. | Rival ...